Alix Seif

Dr. Alix Seif

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2013 in Blood
Verified
Journal Article
Open access
PDF file
DTDavid Trent Teachey
David Trent Teachey
SRSusan R. Rheingold
Susan R. Rheingold
SMShannon L. Maude
Shannon L. Maude
GZGerhard Zugmaier
Gerhard Zugmaier
DBDavid M. Barrett
David M. Barrett
SGStephan A. Grupp
Stephan A. Grupp
Key Points: Cytokine release syndrome caused by T cell-directed therapies may be driven by abnormal macrophage activation and hemophagocytic syndrome. Cytokine-directed therapy can be effective against life-threatening cytokine release syndrome.

27 July 2016 in Nature Communications
Verified
Journal Article
Open access
EJElad Jacoby
Elad Jacoby
SNSang M. Nguyen
Sang M. Nguyen
TFThomas J. Fountaine
Thomas J. Fountaine
KWKathryn Welp
Kathryn Welp
BGBerkley Gryder
Berkley Gryder
TFTerry J. Fry
Terry J. Fry
Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute lymphoblastic leukaemia (ALL). Persisting CAR-T cells generate sustained pressure against CD19 that may drive unique mechanisms of resistance. Pre-B ALL originates from a committed pre-B cell or an earlier progenitor, with potential to reprogram into other hematopoietic lineages. Here we report changes in lineage markers including myeloid conversion in patients following CD19 CAR therapy. Using murine ALL models we study the long-term effects of CD19 CAR-T cells and demonstrate partial or complete lineage switch as a consistent mechanism of CAR resistance depending on the underlying genetic oncogenic driver. Deletion of Pax5 or Ebf1 recapitulates lineage reprogramming occurring during CD19 CAR pressure. Our findings establish lineage switch as a mechanism of CAR resistance exposing inherent plasticity in genetic subtypes of pre-B-cell ALL.

25 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
SMShannon L. Maude
Shannon L. Maude
STSarah Tasian
Sarah Tasian
TVTiffaney Vincent
Tiffaney Vincent
JHJunior W. Hall
Junior W. Hall
CSCecilia Sheen
Cecilia Sheen
DTDavid Trent Teachey
David Trent Teachey
CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been identified in Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL), a recently described subtype of pediatric high-risk B-precursor ALL (B-ALL) which exhibits a gene expression profile similar to Ph-positive ALL and has a poor prognosis. Hyperactive JAK/STAT and PI3K/mammalian target of rapamycin (mTOR) signaling is common in this high-risk subset. We, therefore, investigated the efficacy of the JAK inhibitor ruxolitinib and the mTOR inhibitor rapamycin in xenograft models of 8 pediatric B-ALL cases with and without CRLF2 and JAK genomic lesions. Ruxolitinib treatment yielded significantly lower peripheral blast counts compared with vehicle (P < .05) in 6 of 8 human leukemia xenografts and lower splenic blast counts (P < .05) in 8 of 8 samples. Enhanced responses to ruxolitinib were observed in samples harboring JAK-activating lesions and higher levels of STAT5 phosphorylation. Rapamycin controlled leukemia burden in all 8 B-ALL samples. Survival analysis of 2 representative B-ALL xenografts demonstrated prolonged survival with rapamycin treatment compared with vehicle (P < .01). These data demonstrate preclinical in vivo efficacy of ruxolitinib and rapamycin in this high-risk B-ALL subtype, for which novel treatments are urgently needed, and highlight the therapeutic potential of targeted kinase inhibition in Ph-like ALL.

7 January 2016 in Blood
Verified
Journal Article
Open access
PDF file
KBKaren L. Bride
Karen L. Bride
TVTiffaney Vincent
Tiffaney Vincent
KSKim Smith-Whitley
Kim Smith-Whitley
MLMichele P. Lambert
Michele P. Lambert
JBJack J. Bleesing
Jack J. Bleesing
DTDavid Trent Teachey
David Trent Teachey
Key Points: Sirolimus monotherapy is a safe and effective steroid-sparing agent, improving autoimmune cytopenias in highly refractory patients. Sirolimus is particularly active in ALPS and should be an early therapy option for patients who require chronic therapy.

10 March 2009 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
DTDavid Trent Teachey
David Trent Teachey
RGRobert Greiner
Robert Greiner
ASAlix Seif
Alix Seif
EAEdward Attiyeh
Edward Attiyeh
JBJack Bleesing
Jack Bleesing
SGStephan A. Grupp
Stephan A. Grupp
Summary: We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies. Four patients were treated for autoimmune cytopenias; all had a rapid complete or near complete response. Two patients were treated for autoimmune arthritis and colitis, demonstrating marked improvement. Three patients had complete resolution of lymphadenopathy and splenomegaly and all patients had a reduction in double negative T cells, a population hallmark of the disease. Based on these significant responses, we recommend that sirolimus be considered as second‐line therapy for patients with steroid‐refractory disease.

17 December 2009 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
DTDavid Trent Teachey
David Trent Teachey
ASAlix Seif
Alix Seif
SGStephan A. Grupp
Stephan A. Grupp
Summary: Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of T cell dysregulation caused by defective Fas‐mediated apoptosis. Patients with ALPS can develop a myriad of clinical manifestations including lymphadenopathy, hepatosplenomegaly, autoimmunity and increased rates of malignancy. ALPS may be more common that originally thought, and testing for ALPS should be considered in patients with unexplained lymphadenopathy, hepatosplenomegaly, and/or autoimmunity. As the pathophysiology of ALPS is better characterized, a number of targeted therapies are in preclinical development and clinical trials with promising early results. This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment.